首页> 美国卫生研究院文献>other >Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity
【2h】

Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity

机译:咪唑并喹喔啉抗癌衍生物和咪喹莫特与微管蛋白相互作用:表征与细胞毒性相关的分子微管抑制机制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Displaying a strong antiproliferative activity on a wide variety of cancer cells, EAPB0203 and EAPB0503 belong to the imidazo[1,2-a]quinoxalines family of imiquimod structural analogues. EAPB0503 has been shown to inhibit tubulin polymerization. The aim of the present study is to characterize the interaction of EAPB0203 and EAPB0503 with tubulin. We combine experimental approaches at the cellular and the molecular level both in vitro and in silico in order to evaluate the interaction of EAPB0203 and EAPB0503 with tubulin. We examine the influence of EAPB0203 and EAPB0503 on the cell cycle and fate, explore the binding interaction with purified tubulin, and use a computational molecular docking model to determine the binding modes to the microtubule. We then use a drug combination study with other anti-microtubule agents to compare the binding site of EAPB0203 and EAPB0503 to known potent tubulin inhibitors. We demonstrate that EAPB0203 and EAPB0503 are capable of blocking human melanoma cells in G2 and M phases and inducing cell death and apoptosis. Second, we show that EAPB0203 and EAPB0503, but also unexpectedly imiquimod, bind directly to purified tubulin and inhibit tubulin polymerization. As suggested by molecular docking and binding competition studies, we identify the colchicine binding site on β-tubulin as the interaction pocket. Furthermore, we find that EAPB0203, EAPB0503 and imiquimod display antagonistic cytotoxic effect when combined with colchicine, and disrupt tubulin network in human melanoma cells. We conclude that EAPB0203, EAPB0503, as well as imiquimod, interact with tubulin through the colchicine binding site, and that the cytotoxic activity of EAPB0203, EAPB0503 and imiquimod is correlated to their tubulin inhibiting effect. These compounds appear as interesting anticancer drug candidates as suggested by their activity and mechanism of action, and deserve further investigation for their use in the clinic.
机译:EAPB0203和EAPB0503在多种癌细胞上均表现出强大的抗增殖活性,属于咪喹莫特结构类似物的咪唑并[1,2-a]喹喔啉家族。 EAPB0503已显示抑制微管蛋白聚合。本研究的目的是表征EAPB0203和EAPB0503与微管蛋白的相互作用。为了评估EAPB0203和EAPB0503与微管蛋白的相互作用,我们在细胞和分子水平上结合了体外和计算机模拟实验方法。我们检查EAPB0203和EAPB0503对细胞周期和命运的影响,探索与纯化微管蛋白的结合相互作用,并使用计算分子对接模型确定与微管的结合模式。然后,我们将其与其他抗微管药的药物组合研究用于比较EAPB0203和EAPB0503与已知有效的微管蛋白抑制剂的结合位点。我们证明,EAPB0203和EAPB0503能够在G2和M期阻断人黑素瘤细胞并诱导细胞死亡和凋亡。其次,我们证明EAPB0203和EAPB0503以及意想不到的咪喹莫特直接与纯化的微管蛋白结合并抑制微管蛋白聚合。正如分子对接和结合竞争研究所表明的,我们确定了β-微管蛋白上的秋水仙碱结合位点是相互作用的口袋。此外,我们发现EAPB0203,EAPB0503和咪喹莫特与秋水仙碱合用时显示拮抗的细胞毒作用,并破坏人黑素瘤细胞中的微管蛋白网络。我们得出的结论是,EAPB0203,EAPB0503和咪喹莫特通过秋水仙碱结合位点与微管蛋白相互作用,并且EAPB0203,EAPB0503和咪喹莫特的细胞毒性活性与其微管蛋白抑制作用有关。这些化合物的活性和作用机制表明它们是有趣的抗癌候选药物,值得在临床上进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号